purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation teva earnings call period ending march image source motley fool teva pharmaceutical industry teva q earnings callmay etcontents prepared remark question answer call participant prepared remark operatorhello welcome first quarter teva pharmaceutical industry limited earnings conference call name alex coordinating call today operator instruction hand host ran meir head investor relation please go aheadran meir senior vice president investor relation thank alex thank everyone joining u today hope chance review q result press release along press release announcing positive phase result olanzapine lai trial issued earlier morning copy press release along slide presented call available website irtevapharmcom please review forwardlooking statement slide number additional information statement nongaap financial measure found earnings release sec form k q begin today call richard today call richard francis tevas ceo provide overview tevas firstquarter result business performance recent event focus priority going forward dr eric hughes head rd chief medical officer discus progress innovative pipeline cfo eli kalif follow reviewing firstquarter financial result detail please note today call run approximately one hourand turn call richard richard would please richard francis president chief executive officer thank ran good morning everybody glad could join u morning excited talk result q remind year today almost since launched pivot growth strategy strategy designed get teva back growth pleased say fourth quarter row continuous growth strategy clearly effect go bit detail driving remind bit strategy based four pillar step innovation deliver growth engine step innovation create sustainable generic powerhouse focus business walk achieved area obviously starting show really commercialize innovative product starting show take product clinic think talk bit olanzapine fact brought clinic clinic nine month ahead schedule showing good growth generic business finalize talk tapi got back growth wanted start exciting news olanzapine longacting treatment schizophrenia clinic data readout efficacy study met primary secondary endpoint dose group versus placebo excited dos generally well tolerated safe case pd obviously full submission safety database available second half year really important milestone well patient suffer terrible condition reiterate excited move next slide sort coordinate lefthand side slide see oral molecule used treat schizophrenia see largest olanzapine treat moderate severe also see righthand side slide effective longacting treatment olanzapine significant unmet medical need excited product bringing patient clearly benefit news eric later presentation dive result result constant currency revenue adjusted ebitda nongaap eps net debt stand good start year reconfirming financial outlook let u go bit detail number come driving revenue pleased say fact hitting business sector whether innovative medicine whether generic whether tapi api seeing good growth see austedo growth really good start year ajovy global generic business growing really healthy tapi api back growth let go bit detail starting austedo austedo continues perform really well million quarter versus quarter good strong trx growth momentum confirming guidance billion momentum give confidence excitement around longterm goal get billion revenue wanted use slide remind everybody potential around product unfortunately many patient yet get treatment started directtoconsumer campaign start year make people aware opportunity help address difficult condition need seek help physician encouraging start year austedo look forward momentum continuing moving second part innovative portfolio ajovy good continued growth growing particularly strongly europe international market plea product continue show market share gain yous europe international market showing competitiveness teva sale marketing product like pleased reconfirming guidance half billion moving uzedy newest member innovative family launched product last year momentum continues build continue see good access come fee service medicaid working medicare hospital continue expand coverage seeing good reordering hospital driven favorable product profile recently association psychiatrist meeting u last week believe feedback continues really strong particularly ability therapeutic dos within hour without oral supplement good momentum confirm guidance million confident achieving moving slide give lot pleasure talk generic business sort orientate remember business outside yous continue see continued good growth europe international market say particularly pleased yous growth think highlight pivot growth strategy focus placed generic business make sure bring product market regularly time good supply chain good cost good think start got work encouraging pleased want congratulate team moving another part business excited biosimilar business excited position quarter launching biosimilar humira simlandi getting good interest payer pbms channel regard also pleased fact biosimilar stelara also approved launching february worth pointing portfolio biosimilars launching six really opportunity support pivot growth strategy biosimilars perspective moving step innovation go great detail eric olanzapine already touched upon one thing would like highlight slide capability build execution ability teva olanzapine recruited nine month ahead schedule tla recruiting incredibly well uc cd got icssaba good start supported partnership launch therapeutic abingworth understand asset important patient need focusing showing focus deliver performance want take little minute talk bit capability cns obviously talk lot austedo uzedy ajovy rightly olanzapine get lot attention today building good pipeline come cns giving information move forward building real foundation teva cns moving final pillar focus business around tapi obviously announced start year would divesting tapi api business really pleased see team freedom operate outside teva global billion api market really started deliver got good start growth see momentum growing performance increasing interest got cdmos interest based fact broad technology base credibility quality supply reliability clearly something interested good news come think tapi throughout year close something important u operate company contribute society launched sustainability goal wanted give update progressed regard healthy people launched seven program increase access medicine across globe healthy planet reduced carbon emission versus come conduct business ethical compliance people completed training achieved conclude section would like hand eric head rd ericeric hughes chief medical officer head research development thank richard richard mentioned excited today announced positive primary endpoint readout olanzapine lai program also met secondary endpoint key secondary endpoint thought would start today describing reminding study design executing study today remember study eightweek period randomized placebocontrolled study three dose arm today talking primary readout end eight week study also includes week followup safety executed full randomized patient size subject slightly overenrolled important note second half study read safety second half year come primary efficacy endpoint excited see met clinical significance statistical significance primary endpoint using pan score see score point change baseline score change baseline week eight right expected efficacy clearly efficacious three dose group importantly also total target injection point seen pd injection well tolerated throughout study mention key secondary endpoint include clinical global impression schizophrenia scale personal social performance scale dos achieved clinical significance would like also say study illustrates ability execute accelerate program innovative space brought study nine month real good job clinical team moving austedo continue great work informing patient investigator td running study realworld observational study called impacttd something proud looking patient voice caregiver perspective impact tardive dyskinesia study largest study tardive dyskinesia ever includes wide range age race ethnicity severity baseline movement treatment experience run state united state mentioned developing scale really measuring patient tell u caregiver see come tardive dyskinesia understanding tardive dyskinesia goal educating patient caregiver mission first set data announced presented psych elevate meeting later month moving asthma asthma significant patient population important chronic illness yous around world majority patient use rescue inhaler still million asthma exacerbation every year learned combination rescue inhaler needed fact guideline gina guideline changed point recommendation asthma exacerbation combination beta agonist steroid excited program combination rescue inhaler using albuterol fluticasone two wellknown medication treating physician important thing differentiated device dry powder inhaler important come taking care pediatric patient targeting study excited started phase study point going well great collaborate launch therapeutic help accelerate program even importantly get patient pediatric population going study exciting delivering future new treatment asthmatic exacerbation accordance gina guideline moving last topic antiil program important program first indication taking compound celiac disease il key cytokine pathology celiac disease patient eat gluten cause inflammatory reaction release il activates intraepithelial lymphocyte large patient burden yous million patient half patient diagnosed important thing remember patient still symptom even taking glutenfree diet patient never even respond glutenfree diet patient still want treatment beyond glutenfree diet excited antiil program shown potent antibody rapidly reduces free il level keep level suppressed almost day exploring compound celiac patient right enrolling patient end study end year looking celiac challenge study give single dose tev two week later start glutenfree diet week encouraged see result study hopefully soon important part study really focus symptom patient really impacting feel eat glutencontaining food think potentially differentiated product highaffinity antiil suppresses free il rapidly low immunogenicity date final slide want talk know achieving milestone accelerating shown olanzapine lai today achieved primary endpoint curious hopeful see final set safety data injection second half year antitla program right target enrollment going well ulcerative colitis crohn disease looking interim analysis second half year mentioned antiil program enrolling celiac patient year proofofconcept study excited end month next month see first patient antipdil program oncology finally enrolling phase study working accelerate program dualaction rescue inhaler asthma lot coming looking forward keeping updated going pas eli take awayeli kalif executive vice president chief financial officer thank eric good morning good afternoon everyone begin review q financial result slide starting gaap performance revenue first billion increase yous dollar local currency term compared first quarter increase mainly driven broadbased growth generic product across segment globally including strong contribution generic revlimid yous continued strong growth austedo well ajovy europe international market segment partially offset lower revenue copaxone well anda distribution business yous q recorded gaap operating loss million compared operating loss million quarter last year increase operating loss mainly due higher impairment tangible asset item well higher sale marketing expense first quarter partially offset higher gross profit lower legal settlement loss contingency lower intangible asset impairment first quarter part tevas pivot growth strategy decided divest generic business japan part tevas international market segment asset liability relation business classified held sale first quarter resulted impairment charge approximately million quarter currently expect business sold within next year moving gaap net loss million gaap loss per share quarter compared loss per share q last year lower gaap net loss mainly due higher net loss related noncontrolling interest resulted higher tangible asset impairment related business classified held sale turning slide see total nongaap adjustment first quarter million compared million q notable nongaap adjustment includes legal expense million mainly related estimated provision recorded connection certain litigation case yous notable adjustment include amortization purchased intangible asset million majority included cost sale mentioned impairment tangible asset approximately million related business held sale moving slide review nongaap performance mentioned earlier firstquarter revenue approximately billion increase yous dollar local currency term compared q last year nongaap gross profit margin compared q increase gross margin mainly driven improvement portfolio mix including strong continued growth austedo well decreasing operational cost expected line normal seasonality revenue progression quarter started year lower nongaap profit gross profit margin full year continue expect nongaap gross margin gross margin gradually improve progress throughout year driven continuous improvement portfolio mix strong growth innovative portfolio continuation ongoing cost optimization program moving nongaap operating margin q compared q increase mainly driven higher nongaap gross margin explained partially offset higher sale marketing expense percentage revenue reflecting increased investment support key growth engine including promotional activity related austedo line pivot growth strategy ended quarter nongaap earnings per share compared q mainly driven higher operating income next slide show continuing effort transform optimize global manufacturing operating footprint drive efficiency closed three site bring total footprint plan continue progress end expect close divest four additional site goal bring total number site site really focused continuing optimize operation drive efficiency improve margin turning free cash flow slide free cash flow first quarter million reminder tevas free cash flow tends face headwind start year due timing annual bonus payment paid first quarter every year addition free cash flow q also impacted change certain working capital item today reaffirming free cash flow guidance provided january free cash flow expected range billion billion expect pick next three quarter driven rampup profitability mentioned earlier continue drive working capital improvement turning slide net debt end q billion compared billion end gross debt billion compared billion end decrease gross debt mainly due exchange rate fluctuation million net debt ebitda slightly improved coming time q mainly due higher ebitda subsequent quarter close april repaid million senior note maturity end march st today amount outstanding billion revolving credit facility last week teva entered amendment revolving credit facility update company maximum permitted leverage ratio rcf certain period amendment term rcf company leverage ratio shall exceed four time first quarter time second third fourth quarter time first quarter onwards let u turn attention nongaap outlook slide guided january initially provided fullyear outlook expected revenue earnings progress gradually throughout year continues expectation reported today full year continue expect revenue billion billion also reaffirming nongaap outlook operating income ebitda earnings per share free cash flow provided january like said earlier nongaap gross margin expected full year expect gradual pickup margin second quarter progress second half year line revenue trajectory portfolio mix well improvement ongoing cost optimization program addition continue make deliberate thoughtful investment innovative portfolio progress key pipeline asset drive short longterm growth company similar gross margin improvement also expected see leverage operating expense percentage revenue line rampup revenue progressed throughout year conclude review tevas result first quarter hand back richard summaryrichard francis president chief executive officer thank eli thank based told today continue confident hitting guidance operating income margin net debt two time cash earnings cagr midsingle digit reason remain confident highlight next slide come back execution strategy laid year ago plan return growth accelerate growth sustain growth see made good progress return growth focusing growth engine biosimilars getting generic business back performance accelerate clearly laid foundation olanzapine readout today focus icssaba also highlighted number biosimilars coming think momentum getting around pivot growth continues grow remain optimistic future welcome take question people phone thank question answer operatorthank operator instruction first question today come umer raffat evercore isi line open please go aheadumer raffat evercore isi analyst morning guy thanks taking question congrats phase efficacy portion readout three question today three trialspecific ok first know efficacy delta showing placeboadjusted know lilly ran longacting olanzapine midteens camp perhaps speak clinician want see obviously pd far trumped sort trialtotrial difference placeboadjusted efficacy knowing also got low teen one arm secondly know trial saw acute phase study patient roll safety separate plan maintenance study well think lilly ran ran longacting olanzapine curious impact indication finally noticed guy developed uzedy oral longacting sorry longacting risperidone trial conduct issue led fda issuing crl dosing error documentation issue etc volume injection time efficacy analysis ended get either sensitivity analysis potentially run trial could speak trial conduct looked different study efficacy portion versus way uzedy phase ran thank muchrichard francis president chief executive officer thanks thanks umer thanks question hand straight eric youeric hughes chief medical officer head research development yeah umer thanks question let take third one first crl issue around common problem see schizophrenia problem study sometimes get patient double counted learned lot issue study corrected actually monitor extremely closely ongoing study would say know ability execute study clearly one best industry brought one nine month accelerated well reviewed data carefully issue going forward regard delta saw primary endpoint change pan score baseline week eight blunt delta exactly expect pleased see placebo behaved way something know challenging study every year seem run well record regard lack response placebo delta saw three dos see actually consistent exposure olanzapine across many different study regard hcp would look know clinically significant change expected delta patient investigator would want see able treat patient real benefit know getting efficacy olanzapine single dose month easy subcutaneous injection real benefit program excited see result todayumer raffat evercore isi analyst super helpful thank muchrichard francis president chief executive officer thanks umeroperatorthank next question come david amsellem piper sandler line open please go aheaddavid amsellem piper sandler analyst hey guy couple question biosimilars first talk apologize missed earlier talk impact thinking impact simlandi move year evernorthaccredo contract think secondly know abbvie talked trying enter multiyear contract think phrase teeth thinking aggressive going long term defending brand think mean adoption humira biosimilars second question lastly stelara biosim talk know early sort next year question talk thinking market going behave term aggressive innovator going contracting thinking adoption next year particularly given going launching early biosimilar market formation thank yourichard francis president chief executive officer thank david thanks thanks question take think simlandi year think firstly excited bring market q would say sort build bit second question interest getting payer pbms high think change market versus last year appetite really utilize benefit biosimilars bring market containing healthcare cost long term think dynamic playing obviously built certain amount simlandi forecast year riskadjusted many uncertainty obviously launching moment start year contracting point view something take account would say remain optimistic let u see play think last question think stelara well know interesting two factor one internal got approval going position biosimilar humira coming market later coming market start pointed mean discussion payer pbms six month ahead coming market obviously beneficial factor think show dynamic nature market talked penetration market last year biosimilar humiras general starting see think dynamic situation thing changing definitely hearing payer pbms believe change appetite change strategic thinking see play think consistent saying crystal ball think broad portfolio bring market sensible approach would say optimistic year optimistic next year thanks questiondavid amsellem piper sandler analyst thank youoperatorour next question come ash verma ubs line open please go aheadash verma ubs analyst hi thanks thanks taking question congrats progress two quick followup biosimilar humira think sandoz biosimilar humira interaction primarily cv using exclusionary contracting branded drug believe drive similar level uptake based cigna offering zero copay biosimilars necessarily getting exclusionary contracting tapi see website provide like tapi semaglutide inaudible injectables like level scale something could interest glp player looking significant supply expansion thanksrichard francis president chief executive officer thanks ash thanks thanks call good talk regard contracting sort go back comment earlier dynamic really changed think versus last year many different opportunity emerging normal channel private label evolving almost weekly think u encouraging want try predict going play whether people going mirror people think quite individual think bigger picture encouraged appetite biosimilars whole think know play well obviously u play well think patient society reducing cost long term think everybody waiting see something like could happen think one swallow make summer think really interesting good progress would probably phase obviously speak next quarter earnings think data continuously update regard api raised think know go specific individual api potential u supply capacity obviously hundred api manufacture develop complex probably best way could answer question thanks question ashash verma ubs analyst thanksoperatorour next question come balaji prasad barclays line open please go aheadbalaji prasad barclays analyst hi good morning thanks question couple apology asked richard opportunity speak half dozen neurologist recently general feedback got doc love use austedo want use indication generally think feedback insurance challenge want get experience payer scope commercial team better one two also speak area see offlabel use offlabel potential austedo plan around one two biosimilar side could help notice management commentary biosimilars softened last couple month approval simlandi stelara behind would want revisit expectation around biosimilars would simlandi play guidance seeing reaffirmed even approval thank yourichard francis president chief executive officer thanks balaji thanks question interest first question joint challenge actually good place austedo actually good place xr think insurance issue access issue obviously pocket could different depending speak know think xr still lagging bit behind bid closing fast think know something discus regularly team way something give excuse come driving business forward hopefully answer question regard offlabel obviously know want get discussion think always want make sure product used within label probably much say regard biosimilars smiling think language interpreted softening past think consistently said emerging market dynamic going play want try predict change time rarely happens maybe right one changed quickly quite recently think maybe language around market evolve said crystal ball becoming clearer probably hear one approval two biosimilars certainty may last spoke second thing believe change market see play across whole market seem people making interesting move conversation seem purpose energy ever see play know interesting u start get contract start shift volume start get revenue meaningful know significant change think see evolves go course year balaji thanks questionsbalaji prasad barclays analyst thank youoperatorour next question come jason gerberry bank america line open please go aheadjason gerberry bank america merrill lynch analyst hey guy thanks taking question first one guide wondering really sort key variable getting high end even blowing guidance seems like humira upside optionality guy taking conservative stance get adopted guess exclusive generic either launched yet gotten market share like sandostatin lar korlym maybe upside lever wondering comment dynamic agree characterization secondly olanzapine lai program injection left curious agreement fda margin error single pd event think background rate like kind curious like got unlucky like single case still avoid black box warning thanksrichard francis president chief executive officer thanks thanks jason take stab first one maybe eli join hand eric look think sort actually framed really well bit range need see biosimilars play product launch coming highlighted yous timing uptake see play know see momentum business play think thing waiting happen start happen get clarity think give u opportunity narrow range required think similar range riskadjusted biosimilars riskadjusted new product launch based timing various factor think prudent thing change get certainty come back quickly help understand mean whether mean range narrow maybe eli would like add anything moreeli kalif executive vice president chief financial officer anything add thanksrichard francis president chief executive officer good job hand one eric second oneeric hughes chief medical officer head research development yes question pd discussion fda know discussion around injection would point fda open discussion around know black box warning know monitor closely think important start saying know scientific support rationale clinical data scientifically important note completely different formulation subcutaneous formulation intramuscular injection might hit deep vessel top formulation rapidly aggregate keep api contained almost immediately injection slow release support notion see pd seen mentioned let u see injection mark seen see one would negotiation fda important thing adjudication committee know see accidental pd point think science support pdssjason gerberry bank america merrill lynch analyst great thanksoperatorour next question come yifeng liu hsbc line open please go aheadyifeng liu hsbc analyst good morning thanks taking question got three question first one olanzapine lai could give u update regulatory timeline whether interest filing outside yous second one tla could talk current thinking leveraging diagnostic tool specifically companion diagnosis upon product launch go later pipeline third one biosimilar biden administration recently news substitution without interchangeability wonder upon next probably six biosimilar launch would play role plan whether going change anything study run color would great thank yourichard francis president chief executive officer ok thank question hand first two eric take third oneeric hughes chief medical officer head research development sure thank question regard olanzapine lai know program plan future still running longterm followup hopefully presenting data congress second half year thing drive submission planning submission early stability data product preparedness general timeline olanzapine program regard tla diagnostic tool need see data going interim analysis second half year including different biomarkers could interrogate regard serum biomarkers biopsy biomarkers proteomics genomics predicting response baseline treatment also free tla lot data need look find diagnostic predictive value could really help program certainly use goal treat comer point patient need option get ulcerative colitis crohn disease last question think going handle regard change biosimilars plan fdarichard francis president chief executive officer yeah around interchangeability think something discussed actually concluded proposed need go requires legislation change happen think would say let u see play obviously come substitution allowing biosimilars faster uptake patient payer society would support long way go think embryonic stage see play clarity update subsequent callsyifeng liu hsbc analyst right thanks muchrichard francis president chief executive officer thanks yifengoperatorour next question come thibault boutherin morgan stanley line open please go aheadthibault boutherin morgan stanley analyst yes thank three question first one quick followup biosimilars long term inhouse pipeline mentioned change dynamic thing opening biosimilars changing way willingness invest kind next generation pipeline asset developing internally second question olanzapine market potential mean think gave past kind million million potential uzedy given broad use olanzapine clearly excitement asset know fair think blockbuster potential injectable last question direction offsites saw interest industry biologic capacity elsewhere opportunity potentially divest site monetize site reduction exercise expected site closure thank yourichard francis president chief executive officer ok thank thibault thank question let start first one biosimilar one think around capital allocation see changing dynamic mean would invest internal development think first foremost capital allocation occurs partner well obviously lot le internally want make sure aware allocate capital pipeline partnered le think fortunate position teva makeup business seen innovative pipeline allocating capital accelerating clinic think really drive potential bring lifechanging medicine market also help u drive value shareholder think always thoughtful capital allocation take account thing change business see nothing creates sizable shift strategy right think moved olanzapine prediction around could blockbuster look go back start clearly unmet medical need longacting olanzapine seen data clearly big percentage patient would benefit longacting longacting olanzapine get feedback healthcare physician one reason think study well recruited people wanted part think come giving guidance obviously want bit work understanding dynamic environment come back maybe give bookend later done austedo past something open want give time obviously wanted get safety efficacy readout belt started regard divestment site monetizing virtually would say always done know teva run good site fact reducing site strategy quality site quality people operate site regular occurrence divest sell site people find attractive think obviously talking changing environment around biologics capacity know something may make manufacturing site easier sell see play next year hopefully answer question thibault thank appreciate interestthibault boutherin morgan stanley analyst yeah perfect thank youoperatorour next question come chris schott jp morgan line open please go aheadchris schott jpmorgan chase company analyst oh great thanks much two question maybe first international market twopiece elaborate particularly market driving healthy growth seeing think business whole think part prepared remark talked japanese generic business divesting give u sense large growth profile piece second question coming back tla kind hear term need broad therapy given unmet need space seem like number kols speak also excited potential biomarkerdriven approach help better identify patient guess sort got hand around see biomarker piece something kind secondary study kind broad comer know kind see biomarker sort see potential differentiate biomarkers trying balance like kind entrenched therapy people want something little bit different versus still lot unmet need thanks muchrichard francis president chief executive officer hi chris thanks question regard two international market actually encouraging thing international market growth across growth across time credit team quality team done bit focus investing capital resource specifically think really helped international market one stand think delivering consistent quarteronquarter growth international market know regard japanese business stepping japan divesting part generic business go back capital allocation make sure giving capital generate good return ability thoughtful teva scope geography business play japan tla let hand eric answereric hughes chief medical officer head research development yeah yeah thank question biomarkers tla know number important thing consider talking biomarkers one thing experience biologics discovery biomarkers take large number patient really understand confident biomarkers effect date seen significant delta based biomarkers would like see much bigger delta based many patient certainly possible identify biomarkers predictive response baseline importantly find strong one predictive treatment focused speed focused making sure people option patient like said know patient cycle treatment ulcerative colitis crohn disease need option last want abuse patient possible treatment choice future choice always look biomarkers going take much data todayrichard francis president chief executive officer thanks eric thanks question chrisoperatorthank final question come glen santangelo jefferies line open please go aheadglen santangelo jefferies analyst yeah thanks taking question hey richard wanted shift gear second know prepared remark kind seemed like incrementally excited talk generic business quarter know look result obviously solid growth across geography maybe know could give u little bit detail maybe product launch may driving growth think maybe organic volume business pricing help u ass durability recent trend maybe followup would ask revlimid specifically know created volatility result q q last year based know contract business curious give u update well thanksrichard francis president chief executive officer ok thanks thanks question glen yeah suppose hide excitement look behind appreciate question think said outset write generic business teva component great business use sustainable powerhouse pillar three strategy shying away committing something calling powerhouse reason could extensive pipeline generic teva great highquality manufacturing footprint great gotomarket model reality working perfect harmony still honest making big progress think come new product launch seen q seen year see year know hopefully always rely people give u approval one second thing supply chain supply chain becoming efficient able deliver everincreasing demand thing make excited think linear projection know hard work make happen think year get better better better ingredient quarter started see thing come together think said clear path second revlimid know split product sale think revlimid good example fact know get right rd get right approach market first maximize asset think know something benefiting year also benefiting launch talked call thanks glen thanks question appreciate thank youglen santangelo jefferies analyst ok thank yourichard francis president chief executive officer hey everybody think time would like thank everybody participation interest teva pharmaceutical look forward giving update quarter later year thank youoperatoroperator signoff duration minutescall participantsran meir senior vice president investor relationsrichard francis president chief executive officereric hughes chief medical officer head research developmenteli kalif executive vice president chief financial officerumer raffat evercore isi analystdavid amsellem piper sandler analystash verma ubs analystbalaji prasad barclays analystjason gerberry bank america merrill lynch analystyifeng liu hsbc analystthibault boutherin morgan stanley analystchris schott jpmorgan chase company analystglen santangelo jefferies analyst teva analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy